MG
BIO icon

Michael Gelband’s Bio-Rad Laboratories Class A BIO Stock Holding History

Michael Gelband’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,293
Closed -$1.3M – 1572
2025
Q4 		$1.3M Sell
4,293
-19,179
-82% -$5.98M 0.01% 900
2025
Q3 		$6.58M Sell
23,472
-85,134
-78% -$23.2M 0.07% 315
2025
Q2 		$26.2M Buy
108,606
+64,315
+145% +$15.2M 0.23% 74
2025
Q1 		$10.8M Buy
44,291
+28,484
+180% +$8.57M 0.11% 186
2024
Q4 		$5.19M Buy
+15,807
New +$5.37M 0.04% 435
2024
Q1 		– Sell
-4,544
Closed -$1.47M – 1498
2023
Q4 		$1.47M Buy
4,544
+104
+2% +$32.6K 0.01% 675
2023
Q3 		$1.59M Buy
4,440
+1,411
+47% +$544K 0.02% 759
2023
Q2 		$1.15M Sell
3,029
-4,212
-58% -$1.71M 0.01% 1046
2023
Q1 		$3.47M Buy
7,241
+6,372
+733% +$2.98M 0.03% 656
2022
Q4 		$365K Sell
869
-27,735
-97% -$11.2M 0.01% 1293
2022
Q3 		$11.9M Buy
28,604
+16,090
+129% +$8.02M 0.16% 168
2022
Q2 		$6.19M Sell
12,514
-2,191
-15% -$1.14M 0.08% 336
2022
Q1 		$8.28M Buy
14,705
+9,186
+166% +$5.54M 0.1% 239
2021
Q4 		$4.17M Buy
5,519
+1,980
+56% +$1.48M 0.04% 504
2021
Q3 		$2.64M Buy
+3,539
New +$2.65M 0.04% 614
2021
Q2 		– Sell
-8,765
Closed -$5.01M – 2353
2021
Q1 		$5.01M Buy
8,765
+8,164
+1,358% +$4.83M 0.07% 271
2020
Q4 		$350K Sell
601
-2,959
-83% -$1.69M ﹤0.01% 1450
2020
Q3 		$1.83M Sell
3,560
-2,541
-42% -$1.29M 0.04% 438
2020
Q2 		$2.75M Buy
+6,101
New +$2.69M 0.07% 312
2019
Q4 		– Sell
-35,415
Closed -$11.8M – 1535
2019
Q3 		$11.8M Buy
+35,415
New +$11.6M 0.41% 52

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Michael Gelband's BIO Position: Q1 2026 in Review

Michael Gelband sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2026, closing a stake of 4,293 shares — an estimated $1.3M sold.

Michael Gelband first reported a position in BIO in Q3 2019 and held it in 20 quarters. The position peaked at $26.2M in Q2 2025. 393 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • Michael Gelband reported no remaining Bio-Rad Laboratories Class A position as of Q1 2026 after selling out during the quarter.
  • Michael Gelband sold 4,293 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $1.3M.
  • Michael Gelband first reported a position in Bio-Rad Laboratories Class A in Q3 2019 and held it in 20 quarters.
  • Michael Gelband's Bio-Rad Laboratories Class A position peaked at $26.2M in Q2 2025.
  • 393 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.